David Scheiderer
Psychiatry · Roanoke, VANPI 1699978221
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,949,836 of the $2,381,855 with a category attached, or 81.9%. 15 manufacturers reported payments, led by AbbVie at 36.5% of the total. 2025 is the largest year on record at $508,360, 2.1 times the $246,285 reported in 2019. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,424 payments — averaging $982.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$870K
- Otsuka America Pharmaceutical, Inc.$554K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$496K
- Axsome Therapeutics, Inc.$227K
- Alkermes, Inc.$111K
- Sunovion Pharmaceuticals Inc.$34K
- plus $90K from 9 others
Across 6 payments — averaging $6684.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$40K
What the payments were for
- Consulting fees$161,2907%
- Speaking & faculty fees$1,949,83682%
- Travel & lodging$224,7119%
- Food & beverage$45,8742%
- Education$1440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 921 | $870,270 |
| Otsuka America Pharmaceutical, Inc. | 556 | $553,954 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 427 | $495,839 |
| Axsome Therapeutics, Inc. | 215 | $227,247 |
| Alkermes, Inc. | 121 | $110,614 |
| Sunovion Pharmaceuticals Inc. | 53 | $34,261 |
| Eisai Inc. | 54 | $33,204 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 31 | $14,996 |
| Noven Pharmaceuticals, Inc. | 12 | $12,214 |
| Vanda Pharmaceuticals Inc. | 11 | $11,523 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $9,700 |
| Idorsia Pharmaceuticals US Inc | 2 | $4,606 |
| Merck | 4 | $3,375 |
| Neurocrine Biosciences, Inc. | 1 | $30 |
| Lundbeck LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,381,855 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 12 | $18,906 |
| Clozapine | 12 | $2,013 |
| Olanzapine | 25 | $533 |
| Fluoxetine Hcl | 14 | $123 |
| Lamotrigine | 13 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $495,839 | $18,90612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Roanoke
- Ralph McKenzieRoanoke$161K
- Anita KablingerRoanoke$57K
- Roopa SethiRoanoke$9K
- Niku SinghFalls Church$2.5M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- David SpiegelNorfolk$565K
- William YetterVirginia Beach$312K
- Anita ClaytonCharlottesville$260K
- Robert GardellaStaunton$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.